Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Fresenius Medical (FMS) to EUR 48 from EUR 50 and keeps a Hold rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Hold Rating Maintained for Fresenius Medical Care Amidst Flat US Growth and Downward Financial Adjustments
- Fresenius Medical Care Reports Modest Growth in 2025 Earnings
- Fresenius Medical Care’s Earnings Call Highlights Growth Amid Challenges
- Fresenius Medical Care Restructures with New Value-Based Care Segment
- Fresenius Medical reports Q2 adjusted EPS EUR0.91 vs. EUR0.72 last year